JP2024524870A - 抗ｇａｌ３抗体およびインスリン抵抗性に使用する方法 - Google Patents

抗ｇａｌ３抗体およびインスリン抵抗性に使用する方法 Download PDF

Info

Publication number
JP2024524870A
JP2024524870A JP2023575640A JP2023575640A JP2024524870A JP 2024524870 A JP2024524870 A JP 2024524870A JP 2023575640 A JP2023575640 A JP 2023575640A JP 2023575640 A JP2023575640 A JP 2023575640A JP 2024524870 A JP2024524870 A JP 2024524870A
Authority
JP
Japan
Prior art keywords
gal3
binding fragment
amino acid
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524870A5 (https=
Inventor
サン，ドンフ
トゥンドゥグル，ラガディープティ
リブカ ロズナー，ダリヤ
シチョルス，クセニヤ
Original Assignee
トゥルーバインディング，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トゥルーバインディング，インコーポレイテッド filed Critical トゥルーバインディング，インコーポレイテッド
Publication of JP2024524870A publication Critical patent/JP2024524870A/ja
Publication of JP2024524870A5 publication Critical patent/JP2024524870A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023575640A 2021-06-08 2022-06-07 抗ｇａｌ３抗体およびインスリン抵抗性に使用する方法 Pending JP2024524870A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163202373P 2021-06-08 2021-06-08
US63/202,373 2021-06-08
PCT/US2022/032527 WO2022261113A2 (en) 2021-06-08 2022-06-07 Anti-gal3 antibodies and methods of use for insulin resistance

Publications (2)

Publication Number Publication Date
JP2024524870A true JP2024524870A (ja) 2024-07-09
JP2024524870A5 JP2024524870A5 (https=) 2025-06-17

Family

ID=84426396

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575640A Pending JP2024524870A (ja) 2021-06-08 2022-06-07 抗ｇａｌ３抗体およびインスリン抵抗性に使用する方法

Country Status (5)

Country Link
US (1) US20220411514A1 (https=)
EP (1) EP4352105A4 (https=)
JP (1) JP2024524870A (https=)
CN (1) CN117897406A (https=)
WO (1) WO2022261113A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
US20220411514A1 (en) * 2021-06-08 2022-12-29 Truebinding, Inc. Anti-gal3 antibodies and methods of use for insulin resistance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020160156A2 (en) * 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
JP2020529988A (ja) * 2017-08-03 2020-10-15 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ 医学的障害の予防および治療のための化合物およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR099707A1 (es) * 2014-03-10 2016-08-10 La Jolla Pharma Co Composiciones y métodos para tratar trastornos renales
EP4157338A4 (en) * 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
US20220411514A1 (en) * 2021-06-08 2022-12-29 Truebinding, Inc. Anti-gal3 antibodies and methods of use for insulin resistance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020529988A (ja) * 2017-08-03 2020-10-15 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ 医学的障害の予防および治療のための化合物およびその使用
WO2020160156A2 (en) * 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof

Also Published As

Publication number Publication date
WO2022261113A3 (en) 2023-01-19
EP4352105A2 (en) 2024-04-17
WO2022261113A2 (en) 2022-12-15
CN117897406A (zh) 2024-04-16
EP4352105A4 (en) 2025-09-17
US20220411514A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
CN113423735B (zh) 抗-紧密连接蛋白抗体及其用途
US12497458B2 (en) Anti-GAL3 antibodies and uses thereof
US12281166B2 (en) Methods of treating inflammatory diseases by blocking Galectin-3
US20220411514A1 (en) Anti-gal3 antibodies and methods of use for insulin resistance
CN115427449A (zh) 抗Gal3抗体和使用方法
US20230279120A1 (en) Methods of treating or inhibiting cardiovascular diseases
JP7835441B2 (ja) Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
JP2024526764A (ja) タンパク質凝集を防止する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260331